Indivior Pharmaceuticals (INDV)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for...
- Open
- 38.910
- High
- 39.250
- Low
- 37.640
- Prev. Close
- 39.040
- Volume
- 1.44M
- Turnover
- 54.86M
- Avg Price
- 38.035
- Bid/Ask Ratio
- -69.49%
- Amplitude
- 4.12%
- 52wk High
- 42.810
- Volume Ratio
- 0.91
- Turnover Ratio
- 1.24%
Indivior Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$49.0029.70%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Aug 17 at 04:19 AM
Indivior Q2 2026 Earnings Call: Complete Transcript
- businessinsider · Aug 9 at 09:59 AM
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and more
- MorningStar · Aug 7 at 10:38 AM
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- PUBT · Aug 5 at 03:53 PM
Indivior Chief Accounting Officer Woodrow D Anderson acquires 1,500 shares worth $54,420
- Pharmaceutical Technology · Aug 4 at 05:57 AM
Supernus and Indivior merge to create scaled, CNS-focused entity
- benzinga_article · Aug 4 at 05:04 AM
Top 3 Health Care Stocks You'll Regret Missing This Quarter
